Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$0.72 USD
0.00 (0.31%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.72 0.00 (0.56%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGTX 0.72 0.00(0.31%)
Will CGTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGTX
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
Cognition Therapeutics presents data at AAIC on CT1812 in dementia
Cognition Therapeutics (CGTX) Showcases Promising Study Results at AAIC 2025
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of ...
Cognition Therapeutics (CGTX) Phase 2 Study Reveals Alzheimer's Drug Progress | CGTX Stock News
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of ...